The Evidence Based Rheumatology Podcast

By Michael Putman

A weekly podcast for physicians interested in evidence based medicine and rheumatology. Find the papers at ebrheum.com... more

4.9

114114 ratings

FAQs about The Evidence Based Rheumatology Podcast:

How many episodes does The Evidence Based Rheumatology Podcast have?

The podcast currently has 144 episodes available.

Best of The Evidence Based Rheumatology Podcast

The most played episodes among Podcast App listeners.

Number 1: E137: Obexelimab in IgG4-RD (INDIGO)
Another day, another B cell drug. This one adds an interesting option for IgG4-RD, offering a "maybe less efficacious maybe less toxic" pathway. I could see folks being excited for this, especially in a disease where non-scary-manifestations are relatively common. Also, check out boardsbank.com! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2601337
June 29, 202616min
Number 2: E138: Dapirolizumab for SLE (PHOENYCS-GO)
A new therapy for SLE! This one is a CD40-CD40L blocker, which has some nice new-things to inhibit. The study itself was a qualified success and the podcast got a bit more rant-y than it should have been, but hopefully you get a kick out of it. Paper: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00691-4/fulltext
July 24, 202623min
Number 3: E136: Secukinumab in PMR (REPLENISH)
Big trial this week in the NEJM investigating the IL17 inhibitor secukinumab in PMR. Well worth a read, I would bet on FDA approval in the near future. Some interesting tidbits and of course a weird safety thing we now have to grapple with. Be sure to go to boardsbank.com! Free rheumatology board review, >1000 questions! Paper: https://www.nejm.org/doi/full/10.1056/NEJMoa2602567
June 15, 202614min
Number 4: E134: Brepocitinib in Dermatomyositis (VALOR)
Great trial this week looking at brepocitinib in dermatomyositis. Looks like a winner, expect it will be approved. Where it fits in our approach to IIM is an open question, but nice to have another option. Study: https://www.nejm.org/doi/10.1056/NEJMoa2503531 JC Companion: https://autoimmunedevreport.substack.com/
April 17, 202615min
Number 5: E117: Inebilizumab for IgG4-RD (MITIGATE)
New RCT in a new disease with a new drug! But is it as shiny as one would hope? Interesting discussion today about what a trial means, how it will affect practice, and how we could do better as a field. Happy holidays everyone!
December 03, 202413min